Feedback on ABYSS and beta-blockers, more ESC recap, including SHAM-PVI, FINEARTS-HF, and RESHAPE HF2 trials are the topics John Mandrola, MD, discusses in today’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Feedback on ABYSS Setbacks After Stopping Beta-Blockers https://www.medscape.com/viewarticle/setbacks-after-stopping-beta-blockers-2024a1000fv7 Beta-Blockers Post-MI? No for Me, Even After the ABYSS Trial https://www.medscape.com/viewarticle/beta-blockers-post-mi-no-me-even-after-abyss-trial-2024a1000fva * ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 * REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479 * QOL paper REDUCE AMI https://doi.org/10.1093/ehjcvp/pvae062 * Atenolol ED paper 10.1016/j.ehj.2003.08.016 II. SHAM-PVI * JAMA SHAM-PVI paper https://jamanetwork.com/journals/jama/article-abstract/2823283 * Gupta QOL paper https://pubmed.ncbi.nlm.nih.gov/33952593/ III. FINEARTS HF Finerenone Benefits Heart Failure With Preserved EF https://www.medscape.com/viewarticle/finerenone-benefits-heart-failure-preserved-ef-2024a1000fza Topline Finerenone Results Point to Advance in Heart Failure https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2 * FINEHEARTS -HF NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2407107 * FIDELIO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2025845 * FIGARO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2110956 * Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? https://doi.org/10.1016/j.jacc.2024.08.033 IV. RESHAPE HF TEER in Functional MR: Data Deluge, but No Easy Answers https://www.medscape.com/viewarticle/teer-functional-mr-data-deluge-no-easy-answers-2024a1000fvg * Mitra FR https://www.nejm.org/doi/full/10.1056/NEJMoa1805374 * COAPT https://www.nejm.org/doi/full/10.1056/NEJMoa1806640 * RESHAPE- HF2 https://www.nejm.org/doi/full/10.1056/NEJMoa2314328 * RESHAPE Subgroup paper https://doi.org/10.1016/j.jacc.2024.08.027 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

From ESC: post-MI beta blockers, a new therapy for ATTR-CM, holding RASi before non-cardiac surgery, good news in HFpEF, and an ESC preview are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. ABYSS * ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 * REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479 II. ATTR -CM HELIOS B Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis https://www.medscape.com/viewarticle/positive-top-line-results-vutrisiran-cardiac-amyloidosis-2024a1000cjj * HELIOS A https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985 * HELIOS B https://www.nejm.org/doi/full/10.1056/NEJMoa2409134 III. STOP or NOT Trial * Observational Study Showing Benefits of Holding RASi https://doi.org/10.1097/ALN.0000000000001404 * STOP or NOT Protocol Paper -- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3247-1 * JAMA STOP or NOT https://jamanetwork.com/journals/jama/fullarticle/2823118 IV. GLP1a in HFpEF The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872 * STEP-HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 * STEP-HFpEF-DM https://www.nejm.org/doi/full/10.1056/NEJMoa2313917 * SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 * FLOW https://www.nejm.org/doi/full/10.1056/NEJMoa2403347 * Lancet Meta-analysis https://doi.org/10.1016/S0140-6736(24)01643-X V. ESC Preview Mandrola's Five Big Trials to Look for at ESC 2024 https://www.medscape.com/viewarticle/mandrolas-five-big-trials-look-esc-2024-2024a1000fkt Topline Finerenone Results Point to Advance in Heart Failure https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Suicidal ideation with GLP-1 Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution https://www.medscape.com/viewarticle/signal-suicidality-glp-1-ra-semaglutide-experts-urge-caution-2024a1000fa7 * Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality *   * Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF * PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 * SOLVD https://www.nejm.org/doi/full/10.1056/NEJM199108013250501 * CONSENSUS trial https://www.nejm.org/doi/full/10.1056/NEJM198706043162301 * Meta-analysis of Low vs High Dose ACE/ARB https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956 * Meta-analysis of Sac/Val vs ARB/ACE Inhibitors https://link.springer.com/article/10.1007/s00228-024-03686-6 * PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508 III. CASTLE HTx Critical Appraisal * Critical Appraisal of CASTLE HTx https://doi.org/10.1016/j.jacc.2024.06.020 * CASTLE HTx https://www.nejm.org/doi/10.1056/NEJMoa2306037 * CASTLE AF https://www.nejm.org/doi/full/10.1056/NEJMoa1707855 IV. More Data Suggesting Modest Benefits of the Primary Prevention ICD * First and Recurrent ICD Shocks: JICE Paper from Denmark https://link.springer.com/article/10.1007/s10840-024-01873-0 * HF trialists https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 PROFID Trial https://profid-project.eu/ * DANISH  https://www.nejm.org/doi/full/10.1056/NEJMoa1608029 * SCD-HeFT https://www.nejm.org/doi/full/10.1056/NEJMoa043399 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Diuretic therapy in HFrEF, AF ablation, TACT 2 and the story of subgroups, and SGLT2 inhibitor underuse are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Diuretic Therapy in HF * Dapa vs Metolazone Trial https://doi.org/10.1093/eurheartj/ehad341 ADVOR https://www.nejm.org/doi/10.1056/NEJMoa2203094 II. Rapid Medication Titration for Acute HF * ACC Decision Pathway https://www.jacc.org/doi/10.1016/j.jacc.2024.06.002 III. SGLT2 Inhibitor Use in the US * Shin and Colleagues; JACC  https://www.sciencedirect.com/science/article/abs/pii/S0735109724076332 * Editorial  https://doi.org/10.1016/j.jacc.2024.07.001 IV. AF Ablation: General Anesthesia vs Conscious Sedation * Da Riis-Vestergaard and Colleagues  https://doi.org/10.1093/europace/euae203 V. TACT 2 Published * TACT 1 https://jamanetwork.com/journals/jama/fullarticle/1672238 * TACT 1 DM https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.113.000663 * TACT 2 https://jamanetwork.com/journals/jama/fullarticle/2822472 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Prediction models vs clinical judgement, CCTA quantification of atherosclerosis, AF ablation plus LAAO, atrial shunt devices, and HF medical therapy are topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I.Clinical Prediction Models vs Clinical Judgement Did Statin Decision-Making Just Get Harder?  https://www.medscape.com/viewarticle/did-statin-decision-making-just-get-harder-2024a1000egl * Colunga-Lozano and colleagues * https://doi.org/10.1016/j.jclinepi.2023.10.016 * Aug 02, 2024 This Week in Cardiology Podcast * https://www.medscape.com/viewarticle/1001429 II. CCTA Quantification of Atherosclerosis * Atherosclerosis Quantification and Cardiovascular Risk: the ISCHEMIA Trial https://doi.org/10.1093/eurheartj/ehae471 * Circulation ISCHEMIA sub study 2021 – Severity of CAD and Outcomes https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049755 * ISCHEMIA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1915922 III. Combined AF Ablation and LAAO * Review from Mills and colleagues https://doi.org/10.1016/j.tcm.2023.11.003 * Link to CMS Rule on AF Ablation and LAAO https://hrs2.informz.net/z/cjUucD9taT05MjU3ODgyJnA9MSZ1PTkwMDQ2MTk4MCZsaT04NTU1OTQxMg/index.html IV. Atrial Shunt Devices No Net HF Benefit for Interatrial Shunt Device https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk * Original REDUCE-LAP-HF-II https://doi.org/10.1016/S0140-6736(22)00016-2 * Two-year results of REDUCE-LAP-HF-II https://doi.org/10.1016/j.jchf.2024.04.011 * Apr 19, 2024 This Week in Cardiology Podcast V. Optimal HF Therapy * Rao and colleagues; CHAMP HF https://doi.org/10.1016/j.jchf.2024.05.026 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net